Retatrutide 20MG

Retatrutide (LY3437943) is an investigational triple agonist medication developed by Eli Lilly and Company. It targets three key hormones involved in metabolism and appetite regulation:

• GLP-1 (glucagon-like peptide-1)
• GIP (glucose-dependent insulinotropic polypeptide)
• Glucagon

Unlike dual agonists like tirzepatide (Mounjaro/Zepbound), retatrutide’s triple action has shown superior weight loss in clinical trials—up to 24.2% body weight reduction (about 58 lbs on average) after 48 weeks at the highest dose. It’s primarily studied for:

• Obesity (BMI ≥30 or ≥27 with comorbidities)
• Type 2 diabetes
• Potential benefits in liver fat reduction (MASLD/NAFLD), cardiovascular health, and sleep apnea.

Status: Not FDA-approved yet (as of October 2024). Phase 3 trials (TRIUMPH program) are ongoing, with results expected in 2025. Approval could come in 2026-2027 if successful.

20 mg Dose: What We Know

• Highest studied dose: 20 mg is the maximum from Phase 2 trials (published in NEJM, 2023).
  • Administered once weekly via subcutaneous injection (similar to Ozempic/Wegovy).
  • Titration: Starts low (e.g., 2-4 mg) and ramps up over 12-20 weeks to minimize side effects.
• Efficacy at 20 mg (Phase 2 data, n=338 adults with obesity):

• 58% of participants lost ≥20% body weight.
• Better than semaglutide (15-20%) or tirzepatide (21%) in head-to-head comparisons.

Mechanism Breakdown:

Side Effects & Safety

Common (dose-dependent, mostly GI):

• Nausea (50-60% at 20 mg), vomiting, diarrhea, constipation.
• Heart rate increase (+11 bpm average).
• Milder than predecessors due to glucagon’s muscle-sparing effects (less lean mass loss: ~25% of total vs. 40% with GLP-1 alone).

Rare/Serious:

• Pancreatitis, gallbladder issues, thyroid tumors (black-box warning like other GLP-1s).
• No increased hypoglycemia risk.

Discontinuation: ~16% at 20 mg (mostly GI intolerance).

Availability & Warnings

• Not commercially available: Only in clinical trials. “20 mg vials” sold online are likely counterfeit/repurposed research chems—avoid them.
  • Risks: Incorrect dosing, contamination, unknown purity → hospitalization or death reported with fake semaglutide/tirzepatide.
• Cost estimate (post-approval): $1,000-1,500/month (like Zepbound).
• Compounding pharmacies: Some offer “retatrutide” now, but unverified and illegal without approval.

How to Get It Legally

1. Join a clinical trial (clinicaltrials.gov: search “retatrutide”).
2. Wait for approval—monitor Lilly’s updates.
3. Alternatives now: Tirzepatide (21% loss), semaglutide (15-20%).

Consult a doctor before any weight loss drug. Not for cosmetic use; screen for contraindications (e.g., medullary thyroid cancer history).